Sanofi (SNY): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Sanofi ( SNY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.8%. By the end of trading, Sanofi rose $0.53 (1.0%) to $53.52 on light volume. Throughout the day, 906,099 shares of Sanofi exchanged hands as compared to its average daily volume of 2,354,900 shares. The stock ranged in a price between $53.44-$54.23 after having opened the day at $54.10 as compared to the previous trading day's close of $52.99. Other companies within the Health Care sector that increased today were: USMD Holdings ( USMD), up 21.4%, Escalon Medical Corporation ( ESMC), up 13.8%, Health Management Associates ( HMA), up 11.3% and Hemispherx Biopharma ( HEB), up 11.0%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $142.9 billion and is part of the drugs industry. The company has a P/E ratio of 28.7, above the S&P 500 P/E ratio of 17.7. Shares are up 11.8% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Biota Pharmaceuticals ( BOTA), down 67.3%, Celsion Corporation ( CLSN), down 11.3%, Echo Therapeutics ( ECTE), down 11.3% and Telik ( TELK), down 10.6% , were all laggards within the health care sector with Bristol-Myers Squibb Company ( BMY) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know